Payment overview · 2025
General Payments
$23,009.59
128 reported records · 20 companies
Healthcare provider profile · identity verified
Mark Buchfuhrer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DOWNEY, CA · NPI 1639130693
Verified facts
What the public records show
CMS Open Payments records show Mark Buchfuhrer, MD received $23,009.59 in general payments during 2025 across 128 reported records.
Noctrix Health, Inc. accounted for 88.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Horizant, Nucala, Ofev, Trelegy Ellipta.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Horizant by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ofev by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Belbuca by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 811 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Noctrix Health, Inc. | Unresolved — no canonical attribution shown | $20,302.34 | 88.2% | 22 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $452.76 | 2.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $397.08 | 1.7% | 22 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $364.63 | 1.6% | 13 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $319.54 | 1.4% | 9 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $188.12 | 0.8% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $171.74 | 0.8% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $165.12 | 0.7% | 7 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.75 | 0.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.34 | 0.4% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $90.19 | 0.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $60.99 | 0.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.90 | 0.2% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $42.30 | 0.2% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $35.48 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.83 | 0.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.59 | 0.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.40 | 0.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.27 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.22 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $13,824.00 | 7 |
| Honoraria | $4,585.00 | 11 |
| Food and Beverage | $2,801.33 | 105 |
| Travel and Lodging | $1,610.26 | 3 |
| Education | $189.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NIDRA Normalized: nidra |
Device | Noctrix Health, Inc. | $20,302.34 | 22 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $397.31 | 8 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $319.54 | 9 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $261.93 | 10 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $188.12 | 8 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $186.72 | 10 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $165.12 | 7 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $153.56 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $150.15 | 7 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $149.75 | 8 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $127.26 | 5 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $72.13 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $60.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.21 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.90 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $42.30 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.05 | 1 | 2025 |
Source payment records
|
|||||
| Otezla Normalized: otezla |
Drug | Amgen Inc. | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $30.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.85 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 110 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 811 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
110 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
811 | 173 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 811 | 173 |
| Methadone Hcl | Methadone Hcl | 475 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 323 | 127 |
| Gabapentin | Gabapentin | 274 | 61 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 242 | 70 |
| Oxycodone Hcl | Oxycodone Hcl | 234 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 223 | 66 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 205 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 68 |
| Breo Ellipta | Fluticasone/Vilanterol | 171 | 32 |
| Pregabalin | Pregabalin | 157 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 37 |
| Montelukast Sodium | Montelukast Sodium | 126 | 32 |
| Lisinopril | Lisinopril | 121 | 32 |
| Belbuca | Buprenorphine Hcl | 110 | 16 |
| Prednisone | Prednisone | 108 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 25 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Losartan Potassium | Losartan Potassium | 75 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 70 | 25 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 70 | 19 |
| Metformin Hcl | Metformin Hcl | 63 | 16 |
| Neupro | Rotigotine | 63 | 15 |
| Atenolol | Atenolol | 61 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Horizant | Gabapentin Enacarbil | 49 | suppressed |
| Omeprazole | Omeprazole | 48 | 11 |
| Alprazolam | Alprazolam | 44 | 14 |
| Oxycontin | Oxycodone Hcl | 42 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 11 |
| Simvastatin | Simvastatin | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ofev | Nintedanib Esylate | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Nucala | Mepolizumab | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Pirfenidone | Pirfenidone | 12 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,009.59 · 128 records | Noctrix Health, Inc. | AREXVY, Arikayce, BENLYSTA, BREZTRI, Belbuca, Brinsupri, COSENTYX, DUPIXENT, HORIZANT, JASCAYD, LUMRYZ, MOUNJARO, NIDRA, NUCALA, OFEV, Ohtuvayre, Otezla, PURIFIED CORTROPHIN GEL, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, WAKIX, XYWAV, YUPELRI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Azurity Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error